IBRX stock surges past 4-year highs: Analyst sees over 50% upside after Anktiva’s blowout growth
・H.C. Wainwright raised its price target to $15 from $10, reiterating a 'Buy' rating and implying over 50% upside from current levels. ・Anktiva's full-year net product revenue hit $113 million in 2025, up about 700% from the previous year. ・The...
Stocktwits